In the 10 years since the first results from the Fracture Intervention Trial (FIT) were published,1,2 it has been relatively straightforward to know when to start bisphosphonate therapy for women with postmenopausal osteoporosis. Clear fracture reduction benefit was shown for women with prior vertebral fracture or bone mineral density (BMD) T scores of −2.5 or lower. However, the issue of when to stop bisphosphonate therapy is less clear, and clinical practice guidelines have been almost completely silent on this important decision point.3
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 21
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.